Publications

  1. Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion. Transplantation. 2024 May 21 [Epub ahead of print]
    View PubMed
  2. Seetharam M, Dronca R, Dudek A, Nelson G, Block M, Starling S, Baskin A, Bradshaw R, Nelson C, Andrews K, Birgin A, Watson C, Yan Y, Mahadevan D, Markovic S, Myers T, Paradiso L, Babiker H. Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with BRAF V600-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets) Cancer Research, American Association for Cancer Research. 2024.
  3. Ablooglu AJ, Chen WS, Xie Z, Desai A, Paul S, Lack JB, Scott LA, Eisch AR, Dudek AZ, Parikh SM, Druey KM. Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease. J Clin Invest. 2024 Mar 19; 134 (10)
    View PubMed
  4. Sener U, Webb M, Breen WG, Neth BJ, Laack NN, Routman D, Brown PD, Mahajan A, Frechette K, Dudek AZ, Markovic SN, Block MS, McWilliams RR, Dimou A, Kottschade LA, Montane HN, Kizilbash SH, Campian JL. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. J Immunother Precis Oncol. 2024 Feb; 7 (1):1-6 Epub 2024 Feb 05
    View PubMed
  5. Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Front Immunol. 2023; 14:1279387 Epub 2023 Oct 31
    View PubMed
  6. Danciu OC, Holdhoff M, Peterson RA, Fischer JH, Liu LC, Wang H, Venepalli NK, Chowdhery R, Nicholas MK, Russell MJ, Fan TM, Hergenrother PJ, Tarasow TM, Dudek AZ. Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies. Br J Cancer. 2022 Dec 5 Epub 2022 Dec 05
    View PubMed
  7. Tyler LC, Le AT, Chen N, Nijmeh H, Bao L, Wilson TR, Chen D, Simmons B, Turner KM, Perusse D, Kasibhatla S, Christiansen J, Dudek AZ, Doebele RC. MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC. Thorac Cancer. 2022 Nov; 13(21):3032-3041. Epub 2022 Sep 13.
    View PubMed
  8. Xie Z, Borset M, Sveen K, Boe OW, Chan EC, Lack JB, Hornick KM, Verlicchi F, Eisch AR, Melchio R, Dudek AZ, Druey KM. Markers of endothelial glycocalyx dysfunction in Clarkson disease. J Transl Med. 2022 Aug 29; 20 (1):380
    View PubMed
  9. Johnson M, Dudek AZ, Sukari A, Call J, Kunk PR, Lewis K, Gainor JF, Sarantopoulos J, Lee P, Golden A, Harney A, Rothenberg SM, Zhang Y, Goldman JW. ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. Clin Cancer Res. 2022 Jun 13; 28 (12):2517-2526
    View PubMed
  10. Zylla DM, Eklund J, Gilmore G, Gavenda A, Guggisberg J, VazquezBenitez G, Pawloski PA, Arneson T, Richter S, Birnbaum AK, Dahmer S, Tracy M, Dudek A. A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer. 2021 Dec; 29 (12):7471-7478 Epub 2021 June 04
    View PubMed
  11. Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, Ramalingam SS. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 Nov; 27(11):1910-1920. Epub 2021 Nov 08.
    View PubMed
  12. Hensing TA, Wang X, Stinchcombe TE, Gao J, Knopp MV, Watson M, Dudek AZ, Graziano SL, Patel JD, Faller BA, Dragnev KH, Kozono D, Vokes EE. Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. JTO Clin Res Rep. 2021 Aug; 2 (8):100208 Epub 2021 July 13
    View PubMed
  13. Dudek AZ, Wang X, Gu L, Duong S, Stinchcombe TE, Kratzke R, Borghaei H, Vokes EE, Kindler HL. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 Nov; 21(6):553-561.e1. Epub 2020 Jul 03.
    View PubMed
  14. Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Res Treat. 2020 Oct; 183 (3):617-627 Epub 2020 July 22
    View PubMed
  15. Steele GL, Dudek AZ, Gilmore GE, Richter SA, Olson DA, Eklund JP, Zylla DM. Impact of Pain, Opioids, and the Mu-opioid Receptor on Progression and Survival in Patients With Newly Diagnosed Stage IV Pancreatic Cancer. Am J Clin Oncol. 2020 Aug; 43 (8):591-597
    View PubMed
  16. Alkhateeb HB, Patnaik MM, Al-Kali A, Zblewski DL, Wallerich S, McTavish H, Dudek AZ. Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. Anticancer Res. 2020 Jul; 40 (7):3883-3888
    View PubMed
  17. Han SY, Jahagirdar BN, Dudek AZ. Two Malignancies With Differential Responses to Immune Checkpoint Inhibitors: A Case Report. Anticancer Res. 2020 May; 40 (5):2821-2826
    View PubMed
  18. Dudek AZ, Liu LC, Gupta S, Logan TF, Singer EA, Joshi M, Zakharia YN, Lang JM, Schwarz JK, Al-Janadi A, Alva AS. Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. J Clin Oncol. 2020 Apr 10; 38 (11):1138-1145 Epub 2020 Feb 25
    View PubMed
  19. Hurley PJ, Bose N, Jha G, Gargano M, Ottoson N, Gorden K, Rathmann B, Harrison B, Qiu X, Dudek AZ. Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. Anticancer Res. 2020 Mar; 40 (3):1467-1473
    View PubMed
  20. Balaji Ragunathrao VA, Anwar M, Akhter MZ, Chavez A, Mao Y, Natarajan V, Lakshmikanthan S, Chrzanowska-Wodnicka M, Dudek AZ, Claesson-Welsh L, Kitajewski JK, Wary KK, Malik AB, Mehta D. Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling. Cell Rep. 2019 Dec 10; 29 (11):3472-3487.e4
    View PubMed
  21. Venepalli NK, Emmadi R, Danciu OC, Chowdhery R, Cabay RJ, Gaitonde S, Aardsma N, Kothari R, Liu LC, Fischer JH, Zaidi A, Russell MJ, Dudek AZ. Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. Am J Clin Oncol. 2019 Nov; 42 (11):862-869
    View PubMed
  22. Shah HA, Fischer JH, Venepalli NK, Danciu OC, Christian S, Russell MJ, Liu LC, Zacny JP, Dudek AZ. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors. Am J Clin Oncol. 2019 May; 42 (5):413-420
    View PubMed
  23. Schmidt TM, Liu LI, Abraham IE, Uy AB, Dudek AZ. Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. Anticancer Res. 2018 Jul; 38 (7):4027-4034
    View PubMed
  24. Xie Z, Chen WS, Yin Y, Chan EC, Terai K, Long LM, Myers TG, Dudek AZ, Druey KM. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). J Leukoc Biol. 2018 Apr; 103 (4):749-759 Epub 2018 Jan 23
    View PubMed
  25. Bhattacharyya S, Feferman L, Terai K, Dudek AZ, Tobacman JK. Decline in arylsulfatase B leads to increased invasiveness of melanoma cells. Oncotarget. 2017 Jan 17; 8 (3):4169-4180
    View PubMed
  26. Ganesan C, Obulareddy SJ, Fischer JH, Antonysamy MA, Jha G, Bliss RL, Dudek AZ. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors. Am J Clin Oncol. 2016 Jun; 39 (3):280-7
    View PubMed
  27. Keshtgarpour M, Tan WS, Zwanziger J, Awadalla S, Langi FG, Dudek AZ. Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer. Anticancer Res. 2016 Apr; 36 (4):1759-65
    View PubMed
  28. Saba R, Alsayed A, Zacny JP, Dudek AZ. The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to Therapy. Int J Breast Cancer. 2016; 2016:9768183 Epub 2016 Jan 31
    View PubMed
  29. Javaid S, Terai K, Dudek AZ. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways. Anticancer Res. 2015 Mar; 35 (3):1279-84
    View PubMed
  30. Ojevwe FO, Ojevwe CD, Zacny JP, Dudek AZ, Lin A, Kohlitz P. Treatment of multiple unresectable basal cell carcinomas from Gorlin-Goltz syndrome: a case report. Anticancer Res. 2015 Mar; 35 (3):1777-81
    View PubMed
  31. Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res. 2015 Feb; 25(1):75-9.
    View PubMed
  32. Kim C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. Anticancer Res. 2015 Jan; 35 (1):301-9
    View PubMed
  33. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015; 3:14 Epub 2015 Apr 21
    View PubMed
  34. Litvan J, Aghazarian M, Wiley E, Guleria S, Dudek AZ. Primary peritoneal angiosarcoma: a case report. Anticancer Res. 2014 Sep; 34 (9):5001-6
    View PubMed
  35. Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ. Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma. Am J Clin Oncol. 2014 Jun; 37 (3):261-5
    View PubMed
  36. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res. 2014 May; 34 (5):2405-11
    View PubMed
  37. Dudek AZ, Kumar P, H Thaw SS, Cao Q, Pawloski P, Larson T. Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC. Am J Clin Oncol. 2014 Apr; 37 (2):140-3
    View PubMed
  38. Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. Br J Cancer. 2014 Jan 21; 110 (2):304-12 Epub 2013 Dec 03
    View PubMed
  39. Litterman AJ, Dudek AZ, Largaespada DA. Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination. Oncoimmunology. 2013 Oct 1; 2 (10):e26294 Epub 2013 Oct 15
    View PubMed
  40. Powell SF, Beitinjaneh A, Tessema M, Bliss RL, Kratzke RA, Leach J, Dudek AZ. Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer. Clin Lung Cancer. 2013 Sep; 14 (5):495-501 Epub 2013 June 28
    View PubMed
  41. Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, Dudek AZ, Muller-Mattheis V, Grimm MO, Gschwend JE, Wulfing C, Albers P, Li J, Osmukhina A, Skolnik J, Hudes G. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs. 2013 Aug; 31 (4):1001-7 Epub 2013 Jan 18
    View PubMed
  42. Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, Dudek AZ, Salazar AM, Ohlfest JR. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol. 2013 Jun 15; 190 (12):6259-68 Epub 2013 May 17
    View PubMed
  43. Dudek AZ, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer. 2013 Jun; 11 (2):155-60 Epub 2012 Dec 21
    View PubMed
  44. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar; 344 (3):655-64 Epub 2012 Dec 17
    View PubMed
  45. Sreenivasan V, Dudek AZ. Dystonia in a patient with melanoma metastatic to the brain treated with high-dose interleukin-2, radiation therapy, and levetiracetam. Case Rep Oncol. 2013 Jan; 6 (1):78-83 Epub 2013 Jan 30
    View PubMed
  46. Clement-Duchene C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2012 Oct; 78 (1):57-62 Epub 2012 July 17
    View PubMed
  47. Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol. 2012 Aug; 35 (4):386-92
    View PubMed
  48. Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics. 2012 Jul; 13 (9):1009-21
    View PubMed
  49. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May; 13 (5):539-48 Epub 2012 Mar 26
    View PubMed
  50. Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL, Cancer and Leukemia Group B. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7 (4):755-9
    View PubMed
  51. Liu SV, Truskinovsky AM, Dudek AZ, Ramanathan RK. Metastatic clear cell adenocarcinoma of the urethra in a male patient: report of a case. Clin Genitourin Cancer. 2012 Mar; 10 (1):47-9 Epub 2011 Nov 06
    View PubMed
  52. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012 Mar; 32 (3):1027-31
    View PubMed
  53. Yoseph B, Chi M, Truskinovsky AM, Dudek AZ. Large-cell neuroendocrine carcinoma of the cervix. Rare Tumors. 2012 Jan 2; 4 (1):e18 Epub 2012 Mar 22
    View PubMed
  54. Dudek AZ, Gupta K, Ramakrishnan S, Mukhopadhyay D. Tumor angiogenesis 2012. J Oncol. 2012; 2012:857383. Epub 2012 Aug 02.
    View PubMed
  55. Chi M, Dudek AZ, Wind KP. Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors. Onkologie. 2012; 35 (4):210-4 Epub 2012 Mar 15
    View PubMed
  56. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olyaee MS, Esfandyari T, Farassati F. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One. 2012; 7 (4):e33214 Epub 2012 Apr 02
    View PubMed
  57. Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011 Dec; 24(6):1148-57.
    View PubMed
  58. Bommakanti SV, Dudek AZ, Khatri A, Kirstein MN, Gada PD. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors. Am J Clin Oncol. 2011 Dec; 34 (6):597-602
    View PubMed
  59. Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011 Nov 20; 29(33):4436-41. Epub 2011 Oct 03.
    View PubMed
  60. Zhang H, Li W, Franklin MJ, Dudek AZ. Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. Anticancer Res. 2011 Nov; 31 (11):3945-52
    View PubMed
  61. Jasinski P, Zwolak P, Isaksson Vogel R, Bodempudi V, Terai K, Galvez J, Land D, Dudek AZ. MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis. Invest New Drugs. 2011 Oct; 29 (5):846-52 Epub 2010 Apr 16
    View PubMed
  62. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant. 2011 Jul-Aug; 25 (4):541-8 Epub 2010 Nov 02
    View PubMed
  63. Chi M, Dudek AZ. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res. 2011 Jun; 21 (3):165-74
    View PubMed
  64. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011 May 15; 117 (10):2202-8 Epub 2010 Nov 29
    View PubMed
  65. Jasinski P, Zwolak P, Terai K, Vogel RI, Borja-Cacho D, Dudek AZ. MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling. Anticancer Res. 2011 Apr; 31 (4):1181-7
    View PubMed
  66. Jasinski P, Zwolak P, Terai K, Borja-Cacho D, Dudek AZ. PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis. Invest New Drugs. 2011 Feb; 29 (1):33-40 Epub 2009 Oct 01
    View PubMed
  67. Bodempudi V, Ohlfest JR, Terai K, Zamora EA, Vogel RI, Gupta K, Hebbel RP, Dudek AZ. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Ther. 2010 Dec; 17 (12):855-63 Epub 2010 Aug 20
    View PubMed
  68. Dudek AZ. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Transl Res. 2010 Sep; 156 (3):136-46 Epub 2010 July 30
    View PubMed
  69. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, Dudek AZ. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer. 2010 Sep 1; 11 (5):E1-4
    View PubMed
  70. Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol. 2010 Aug; 85(8):593-8.
    View PubMed
  71. Obulareddy SJ, Xin J, Truskinovsky AM, Anderson JK, Franklin MJ, Dudek AZ. Metanephric adenoma of the kidney: an unusual diagnostic challenge. Rare Tumors. 2010 Jun 30; 2 (2):e38 Epub 2010 June 30
    View PubMed
  72. Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, Dudek AZ, Vokes EE, Green MR, Cancer and Leukemia Group B, North Central Cancer Treatment Group, Radiation Therapy Oncology Group. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol. 2010 Jun; 5(6):810-7.
    View PubMed
  73. Kamada P, Dudek AZ. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Cancer Invest. 2010 Jun; 28 (5):501-4
    View PubMed
  74. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20; 28 (15):2598-603 Epub 2010 Apr 12
    View PubMed
  75. Antony GK, Bertino E, Franklin M, Otterson GA, Dudek AZ. Small cell lung cancer in never smokers: report of two cases. J Thorac Oncol. 2010 May; 5 (5):747-8
    View PubMed
  76. Dudek AZ, Yee RT, Manivel JC, Isaksson R, Yee HO. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Anticancer Res. 2010 Mar; 30 (3):987-92
    View PubMed
  77. Dudek A, Gupta K, Ramakrishnan S, Mukhopadhyay D. Tumor angiogenesis. J Oncol. 2010; 2010 Epub 2010 Sept 19
    View PubMed
  78. Powell SF, Dudek AZ. Treatment of melanoma-associated retinopathy. Curr Treat Options Neurol. 2010 Jan; 12(1):54-63.
    View PubMed
  79. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, Cheng EY. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am. 2010 Jan; 92 (1):162-8
    View PubMed
  80. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010; 17 (29):3297-302
    View PubMed
  81. Spector E, Franklin MJ, Truskinovsky AM, Dudek AZ. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol. 2010; 49 (1):104-6
    View PubMed
  82. Dudek AZ, Murthaiah PK, Franklin M, Truskinovsky AM. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor. Acta Oncol. 2010; 49 (1):101-4
    View PubMed
  83. Wcislo R, Dzwinel W, Yuen DA, Dudek AZ. A 3-D model of tumor progression based on complex automata driven by particle dynamics. J Mol Model. 2009 Dec; 15 (12):1517-39 Epub 2009 May 23
    View PubMed
  84. Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer. 2009 Oct 6; 101 (7):1114-23
    View PubMed
  85. Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res. 2009 Oct 1; 15 (19):6137-47 Epub 2009 Sept 29
    View PubMed
  86. Powell S, Dudek AZ. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res. 2009 Oct; 29 (10):4189-93
    View PubMed
  87. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, Hughes PJ, Michalowicz BS, Leach JW, Swenson KK, Swift JQ, Adkinson C, Basi DL. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009 Sep; 67 (9):1904-13
    View PubMed
  88. Dudek AZ, Lesniewski-Kmak K, Larson T, Dragnev K, Isaksson R, Gupta V, Maddaus MA, Kratzke RA. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. J Thorac Oncol. 2009 Aug; 4 (8):969-75
    View PubMed
  89. Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, Babovick-Vuksanovic D, Woo RA, Mautner VF, Kluwe L, Clapp DW, De Vries GH, Thomas SL, Kurtz A, Parada LF, Farassati F. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol. 2009 Jul; 29(14):3964-74. Epub 2009 May 04.
    View PubMed
  90. McTavish H, Griffin RJ, Terai K, Dudek AZ. Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. Transl Res. 2009 Jun; 153 (6):275-82 Epub 2009 Mar 14
    View PubMed
  91. Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer. 2009 May 5; 100 (9):1379-84
    View PubMed
  92. Murthaiah P, Truskinovsky AM, Shah S, Dudek AZ. Collision tumor versus multiphenotypic differentiation: a case of carcinoma with features of colonic and lung primary tumors. Anticancer Res. 2009 May; 29 (5):1495-7
    View PubMed
  93. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009 Jan 1; 115 (1):61-7
    View PubMed
  94. Powell SF, Dudek AZ. Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. Pharmgenomics Pers Med. 2009; 2:21-37 Epub 2009 June 24
    View PubMed
  95. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek A, Potter DA, Woo RA, O'Rourke DM, Tindall DJ, Farassati F. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther. 2008 Nov; 7(11):3586-97.
    View PubMed
  96. Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Clohisy DR, Dudek AZ. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer. 2008 Nov; 44 (16):2506-17 Epub 2008 Aug 22
    View PubMed
  97. Jasinski P, Zwolak P, Terai K, Dudek AZ. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. Transl Res. 2008 Nov; 152 (5):203-12 Epub 2008 Oct 11
    View PubMed
  98. Leone JP, Dudek AZ. Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer. Anticancer Res. 2008 Nov-Dec; 28 (6B):3937-9
    View PubMed
  99. Dudek AZ, Nguyen S. Safety of nab-paclitaxel plus sunitinib: analysis of three cases. Anticancer Res. 2008 Sep-Oct; 28 (5B):3099-105
    View PubMed
  100. Jasinski P, Welsh B, Galvez J, Land D, Zwolak P, Ghandi L, Terai K, Dudek AZ. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs. 2008 Jun; 26 (3):223-32 Epub 2007 Oct 24
    View PubMed
  101. Jasinski P, Terai K, Zwolak P, Dudek AZ. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. Eur J Cancer. 2008 Jun; 44 (9):1315-22 Epub 2008 Apr 28
    View PubMed
  102. Whitson BA, Groth SS, Andrade RS, Garrett L, Dudek AZ, Jessurun J, Maddaus MA. Extension of survival by resection of asynchronous renal cell carcinoma metastases to mediastinal lymph nodes. J Thorac Cardiovasc Surg. 2008 May; 135 (5):1022-8
    View PubMed
  103. Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol. 2008 Apr; 3(4):394-9.
    View PubMed
  104. Dudek AZ, Chereddy S, Nguyen S, Wagner JE, Maddaus M. Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemia. J Thorac Oncol. 2008 Apr; 3 (4):447-50
    View PubMed
  105. Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol. 2008 Apr; 31 (2):173-81
    View PubMed
  106. Nguyen S, Franklin M, Dudek AZ. Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. Transl Res. 2008 Apr; 151 (4):194-6 Epub 2008 Feb 06
    View PubMed
  107. Subhadra C, Dudek AZ, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol. 2008 Mar; 28 (1):23-6
    View PubMed
  108. Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res. 2008 Mar; 151 (3):129-33
    View PubMed
  109. Dudek AZ, Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Farassati F. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs. 2008 Feb; 26 (1):13-24 Epub 2007 Sept 06
    View PubMed
  110. Zwolak P, Dudek AZ, Bodempudi VD, Nguyen J, Hebbel RP, Gallus NJ, Ericson ME, Goblirsch MJ, Clohisy DR. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer. 2008 Feb 1; 122 (3):681-8
    View PubMed
  111. Dham A, Truskinovsky AM, Dudek AZ. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol. 2008 Jan; 3 (1):94-7
    View PubMed
  112. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007 Dec 1; 13 (23):7119-25
    View PubMed
  113. Dudek AZ, Larson T, Keshtgarpour M, Kumar P. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer. Am J Clin Oncol. 2007 Oct; 30 (5):481-6
    View PubMed
  114. Dudek AZ, Bodempudi V, Welsh BW, Jasinski P, Griffin RJ, Milbauer L, Hebbel RP. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer. 2007 Aug 20; 97 (4):513-22 Epub 2007 July 24
    View PubMed
  115. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May 20; 25 (15):2078-85
    View PubMed
  116. Mulamalla K, Truskinovsky AM, Dudek AZ. Pulmonary blastoma with renal metastasis responds to sorafenib. J Thorac Oncol. 2007 Apr; 2 (4):344-7
    View PubMed
  117. Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res. 2007 Mar; 149 (3):103-6
    View PubMed
  118. Kirstein MN, Moore MM, Dudek AZ. Review of selected patents for cancer therapy targeting tumor angiogenesis. Recent Pat Anticancer Drug Discov. 2006 Jun; 1(2):153-61.
    View PubMed
  119. Dudek AZ, Mahaseth H. Hematopoietic stem cell transplant-related airflow obstruction. Curr Opin Oncol. 2006 Mar; 18(2):115-9.
    View PubMed
  120. Dudek AZ, Arodz T, Gálvez J. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb Chem High Throughput Screen. 2006 Mar; 9(3):213-28.
    View PubMed
  121. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 2006 Jan; 51(1):89-96. Epub 2005 Nov 14.
    View PubMed
  122. Arodz T, Yuen DA, Dudek AZ. Ensemble of linear models for predicting drug properties. J Chem Inf Model. 2006 Jan-Feb; 46(1):416-23.
    View PubMed
  123. Miller JS, Curtsinger J, Berthold M, Malvey K, Bliss RL, Le CT, Fautsch SK, Dudek AZ, Blazar BR, Panoskaltsis-Mortari A. Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. Clin Immunol. 2005 Nov; 117(2):144-51. Epub 2005 Aug 19.
    View PubMed
  124. Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005 Feb 11; 280(6):4948-58. Epub 2004 Nov 05.
    View PubMed
  125. Dudek AZ, Lesniewski-Kmak K, Bliss RL, Brunstein C, Condon DL, Kratzke RA. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung. 2005 Jan-Feb; 183(1):43-52.
    View PubMed
  126. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 2005; 23(3):193-200.
    View PubMed
  127. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003 Oct; 9(10):657-66.
    View PubMed
  128. Dudek AZ, Pawlak WZ, Kirstein MN. Molecular targets in the inhibition of angiogenesis. Expert Opin Ther Targets. 2003 Aug; 7(4):527-41.
    View PubMed
  129. Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood. 2003 Jun 15; 101(12):4687-94. Epub 2003 Feb 13.
    View PubMed
  130. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002 Mar 1; 20 (5):1182-91
    View PubMed
  131. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2002 Feb; 109 (3):337-46
    View PubMed
  132. Gupta P, Oegema TR Jr, Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. Blood. 2000 Jan 01; 95(1):147-55.
    View PubMed
  133. Gupta P, Oegema TR Jr, Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood. 1998 Dec 15; 92(12):4641-51.
    View PubMed
  134. Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C. J Biol Chem. 1997 Dec 12; 272(50):31785-92.
    View PubMed